Jeffrey R. Janek serves as the Vice President of Production Operations at ADMA Biologics, Inc., where he leverages his extensive experience in the pharmaceutical and biologic manufacturing sectors to drive operational excellence. With a robust background in leading manufacturing operations across North and South America,...
Jeffrey R. Janek serves as the Vice President of Production Operations at ADMA Biologics, Inc., where he leverages his extensive experience in the pharmaceutical and biologic manufacturing sectors to drive operational excellence. With a robust background in leading manufacturing operations across North and South America, Jeffrey is adept at overseeing the end-to-end processes involved in Human Plasma Fractionation, Purification, and the aseptic filling of IVIG drug therapies. His role encompasses not only the management of production operations but also the strategic deployment of Manufacturing Operation Systems and the development of Organizational Design, positioning him as a subject matter expert in these critical areas.
Under Jeffrey's leadership, ADMA Biologics has successfully navigated complex technology transfers and new product launches, ensuring compliance with stringent regulatory standards in both U.S. and international markets. His commitment to quality systems, including adherence to ISO 13485 standards, has been instrumental in enhancing safety and productivity within the manufacturing environment. Jeffrey's proficiency in the Theory of Constraints and cross-functional team leadership fosters a culture of continuous improvement, enabling the organization to optimize processes and achieve operational efficiencies.
As a visionary executive, Jeffrey is dedicated to advancing the capabilities of ADMA Biologics, ensuring that the company remains at the forefront of the biologics industry. His strategic insights and hands-on approach not only enhance the company's manufacturing operations but also contribute significantly to the health and well-being of patients with compromised immune systems, underscoring his commitment to making a meaningful impact in the field of biopharmaceuticals.
